Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Advanced Liver Cancer Market Size Shifted, And What Is the Outlook Through 2034?

The market size for advanced liver cancer has seen significant expansion in the past few years. This market is projected to rise from a worth of $1.89 billion in 2024 to about $2.16 billion in 2025, experiencing a compound annual growth rate (CAGR) of 14.5%. Factors contributing to growth during the previous period include heightened awareness about liver cancer, a larger patient population, greater demand for focused treatments, the development of healthcare infrastructure, and an increasing preference for less invasive procedures.

Experts predict a swift upswing in the advanced liver cancer market in the upcoming years, with its value potentially hitting $3.74 billion in 2029—this represents a compound annual growth rate (CAGR) of 14.7%. This anticipated growth over the forecast period is primarily due to the rising frequency of liver cancer, growing healthcare expenditure, increased prevalence of genetic diseases, rising use of precision medicine, and wider use of screening and diagnostic tests. Key trends expected during this period range from incorporating artificial intelligence in therapies, development of avant-garde drugs and treatments, burgeoning research and development pursuits, advances in targeted therapeutics, to the escalating demand for individualized treatments.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20706&type=smp

Which Factors and External Forces Are Driving Demand in the Advanced Liver Cancer Market?

The escalating occurrence of chronic hepatitis infections is projected to drive the expansion of the advanced liver cancer market. Chronic hepatitis infections are persistent viral diseases lasting over six months, potentially leading to liver damage, cirrhosis, or liver cancer. The surge in such infections can be traced back to issues such as insufficient screening and vaccination, along with deferred treatment access. Chronic hepatitis B (HBV) or hepatitis C (HCV) infections are among the top triggers for liver cirrhosis and hepatocellular carcinoma (HCC), which is the most prevalent type of liver cancer. These enduring viral infections can ultimately result in liver inflammation, liver damage, and then cancer over an extended period. As the incidence of these infections remains high, more people are consequently exposed to the risk of advanced liver cancer. For example, the World Health Organization, an intergovernmental agency based in Switzerland, stated in April 2024 that in 2022, chronic Hepatitis B had impacted 254 million people globally, with 1.2 million fresh cases reported annually. Consequently, the surge in chronic hepatitis infections is fueling the expansion of the advanced liver cancer market.

Which Segments in the Advanced Liver Cancer Offer the Most Growth?

The advanced liver cancermarket covered in this report is segmented –

1) By Test Type: Imaging Test; Biopsy; Genomic Test; Other Test Types

2) By Technology: Fluorescent In Situ Hybridization; Next Generation Sequencing; Fluoroimmunoassay; Comparative Genomic Hybridization; Immunohistochemical; Other Technologies

3) By Distribution Channel: Direct Tenders; Retail Sales; Other Distribution Channel

4) By Application: Screening; Diagnostic And Predictive; Prognostic; Research

5) By End-User: Hospitals; Cancer Research Centers; Academic Institutes; Diagnostic Centers; Ambulatory Surgical Centers; Other End-Users

Subsegments:

1) By Imaging Test: Ultrasound; CT (Computed Tomography) Scan; MRI (Magnetic Resonance Imaging); PET (Positron Emission Tomography) Scan

2) By Biopsy: Needle Biopsy; Laparoscopic Biopsy; Surgical Biopsy

3) By Genomic Test: Next-Generation Sequencing (NGS); PCR (Polymerase Chain Reaction) Testing; Genetic Mutation Profiling

4) By Other Test Types: Serum Biomarker Testing; Liver Function Tests; Alpha-Fetoprotein (AFP) Test; Elastography Tests

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20706&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Advanced Liver Cancer Market?# Market?

North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theAdvanced Liver Cancer Market’s Growth?

In the advanced liver cancer sector, primary corporations are committed to the production of innovative treatments like human monoclonal antibodies aimed at enhancing treatment potency and reducing adverse effects, thus improving patient prognoses. The human monoclonal antibody, a laboratory-engineered molecule, effectively mimics the immune system’s action against harmful pathogens or cancer cells, recognizing particular antigens on these destructive entities and inducing an immune defense. As an illustration, American pharmaceutical firm AstraZeneca revealed in October 2022 that the US Food and Drug Administration (FDA) granted approval to Imjudo (tremelimumab) used alongside Imfinzi (durvalumab) to treat adult patients with incurable hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The approval was influenced by the HIMALAYA Phase III trial outcomes, which showed that this combined treatment could lower mortality risk by 22% in comparison to sorafenib, leaving approximately 31% of the patients alive after three years as against just 20% for the sorafenib group. With the designated STRIDE regimen, initially, a single Imjudo dose is administered, followed by regular Imfinzi doses every four weeks, thus providing a fresh treatment alternative for patients with scarce options.

View the full report here:

https://www.thebusinessresearchcompany.com/report/advanced-liver-cancer–global-market-report

What Are the Key Elements That Define the Advanced Liver Cancer Market?

Advanced liver cancer, also known as hepatocellular carcinoma (HCC) in its later stages, refers to liver cancer that has spread beyond the liver or grown large enough to affect liver function significantly. In this stage, the cancer may have invaded nearby blood vessels, lymph nodes, or distant organs, making treatment more challenging. Symptoms often include jaundice, abdominal pain, weight loss, and fatigue.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20706

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model